论文部分内容阅读
目的 研究 C D4 4 和n m 2 3 在肾脏肿瘤中表达情况。 方法 采用免疫组化 L S A B 法对10 例肾脏良性肿瘤,38 例肾脏恶性肿瘤及6 例转移淋巴结中的 C D4 4 和nm 23 表达情况进行检测,并进行临床随访。 结果 C D4 4 在肾恶性肿瘤中表达阳性率显著高于肾良性肿瘤,且高分期肿瘤阳性率显著高于低分期肿瘤。n m23 在肾脏良、恶性肿瘤间表达无差别,亦与分期无关,但在有转移的肾癌中均呈阴性表达。随访2 年,nm 23 、 C D4 4 不能单独判断预后,但 C D4 4 阳性、n m23 阴性的肾癌预后较差。 结论 C D4 4 在肾脏恶性肿瘤的发生、浸润中发挥作用,nm 23 对限制肿瘤的转移有一定的影响。 C D4 4 和n m23 联合检测,可作为判断肾癌的预后指标。
Objective To investigate the expression of C D4 4 and n m 2 3 in renal tumors. Methods The expressions of C D4 4 and nm 23 in 10 cases of renal benign tumor, 38 cases of renal malignant tumor and 6 cases of metastatic lymph nodes were detected by immunohistochemical L S A B method and were followed up. Results The positive expression rate of C D4 4 in renal malignant tumors was significantly higher than that of benign neoplastic tumors, and the positive rate of C D4 4 was significantly higher than that in low-staged tumors. There was no difference in the expression of n m23 between benign and malignant nephridial tumors, and no correlation with staging. However, it was negative in metastatic renal cell carcinoma. The follow-up of 2 years, nm 23, C D4 4 can not judge the prognosis alone, but C D4 4 positive, n m23-negative renal cell carcinoma with poor prognosis. Conclusions C D4 4 plays a role in the occurrence and infiltration of renal malignancies. Nm 23 has certain influence on the restriction of tumor metastasis. C D4 4 and n m23 joint detection, can be used as a prognostic indicator of renal cell carcinoma.